Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Circ Heart Fail. 2016 Oct;9(10):e002962. doi: 10.1161/CIRCHEARTFAILURE.115.002962

Figure 4. Risk of Event for ≥5 Units LVEF 12-Month Change Stratified by Subgroup.

Figure 4

Figure 4

Figure 4

Hazard Ratio with 95% confidence intervals are shown for subgroups 4a. treatment group (bucindolol and placebo), 4b. race (African-American, AA and Non-African-American, Non-AA), and 4c. sex.1 indicates Cox model test for significance of treatment × LVEF response indicator interaction;2, Cox model test for significance of race × LVEF response indicator interaction;3, Cox model test for significance of sex × LVEF response indicator interaction; ACM, all-cause mortality; CVM, cardiovascular mortality; and HFH, heart failure hospitalization.